Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.

Burmeister JR, Jawad M, Zazay I, Kobernick A

SAGE open medical case reports2 Sept 2026

PMID42694263 (opens in a new tab)PMCIDPMC13538991 (opens in a new tab)DOI10.1177/2050313x261486164 (opens in a new tab)PepBankPUB-42694263
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Patulous Eustachian tube dysfunction (PETD) is an uncommon condition characterized by an abnormally patent Eustachian tube, leading to symptoms such as aural fullness and autophony. Rapid weight loss is a recognized risk factor due to loss of peritubal adipose support. With the increasing use of semaglutide and other glucagon-like peptide-1 receptor agonists for obesity management, substantial and rapid weight reduction has become more common, raising the potential for underrecognized otologic complications. A 79-year-old male presented with intermittent bilateral aural fullness and ear "popping" without associated pain, vertigo, or systemic symptoms. His history was notable for intentional weight loss of approximately 200 lb following initiation of semaglutide therapy. Otoscopic examination was unremarkable, and prior tympanometry demonstrated normal middle ear pressure. In the absence of findings suggestive of obstructive Eustachian tube dysfunction, a clinical diagnosis of patulous Eustachian tube dysfunction was made. The patient was managed conservatively with hydration, intranasal saline, and avoidance of decongestants. Rapid, extreme weight loss associated with GLP-1 receptor agonist therapy may precipitate PETD and should be considered in patients presenting with aural fullness and normal middle ear findings. Recognition of this association supports appropriate conservative management and may prevent unnecessary interventions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 79-year-old man, patulous Eustachian tube dysfunction was diagnosed after rapid weight loss of about 200 lb following semaglutide initiation.

    In plain wordsIn one older man, an ear problem called patulous Eustachian tube dysfunction was diagnosed after large weight loss on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatulous Eustachian tube dysfunction after rapid weight loss
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His history was notable for intentional weight loss of approximately 200 lb following initiation of semaglutide therapy.
    2 context sentences
    Summary · context
    In the absence of findings suggestive of obstructive Eustachian tube dysfunction, a clinical diagnosis of patulous Eustachian tube dysfunction was made.
    Summary · context
    A 79-year-old male presented with intermittent bilateral aural fullness and ear "popping" without associated pain, vertigo, or systemic symptoms.
  2. 02HumanCase report or seriesEfficacy outcome

    A 79-year-old man lost approximately 200 lb after starting semaglutide.

    In plain wordsOne older man lost about 200 lb after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss after semaglutide initiation
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    ≈ 200 lb
    case

    Source sentences

    Summary
    His history was notable for intentional weight loss of approximately 200 lb following initiation of semaglutide therapy.
    1 context sentence
    Summary · context
    A 79-year-old male presented with intermittent bilateral aural fullness and ear "popping" without associated pain, vertigo, or systemic symptoms.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.